Moreover, silencing cystatin B, an endogenous inhibitor of cysteine proteases, in AD mouse models reduced intraneuronal accumulation of Aβ40 and Aβ42 and improved behavioral outcomes. Here, CTSB is linked to Alzheimer disease.